Alspaugh Jonathan
- SEC CIK
- 0001868112
No open-market purchases or sales filed in the past year.
Current role at each company
- SYRE Spyre Therapeutics, Inc.President and CFOas of Jun 30, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Alspaugh Jonathan as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 15, 2022 (view filing) | Mar 11 | 4 days | Alspaugh JonathanChief Financial Officer | PPurchase | +75.0K | $2.08 | +$156.0K | +83.0%165.4K after | |
| Dec 13, 2021 (view filing) | Dec 9 | 4 days | Alspaugh JonathanChief Financial Officer | PPurchase | +50.0K | $3.72 | +$186.0K | +123.8%90.4K after | |
| Aug 18, 2021 (view filing) | Aug 16-18 | 2 days | Alspaugh JonathanChief Financial Officer | PPurchase | +40.4K | $6.51 | +$262.7K | New position40.4K after | 3 lots |